Please login to the form below

Not currently logged in

UCB reports H1 profit rise

UCB's profit has been boosted by increased sales of core drugs

UCB, the Belgian pharmaceutical company, has posted an 11 per cent increase in pre-tax profit to €443m for the first six months of 2011, reflecting a strong increase in sales.

The company's total revenue for the period increased by 2 per cent to €1.68bn. It reported significant sales growth of new medicines Cimzia (certolizumab pegol - 72 per cent), Vimpat (lacosamide - 76 per cent) and Neupro (rotigotine - 17 per cent). UCB also noted a strong performance of its anti-epileptic drug Keppra (levetiracetam) in Europe and Japan.

Roch Doliveux, CEO, said: "We are excited about the momentum of Cimzia, Vimpat and Neupro, about the potential UCB new medicines from our promising pipeline and about the fact that from 2012 onward, we will have a decade without impacts from major patent expiries."

The company's pipeline has been strengthened with positive phase III results for Cimzia in rheumatoid arthritis and Neupro for advanced Parkinson's disease.

29th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...